National University Galway spin-out called Orbsen Therapeutics has begun clinical trials which center on liver disease in the hopes of reducing the need for transplants. The investigational immunotherapy, known as ORBCEL is being administered in the UK to determine its effectiveness and safety. The hope is that it will address conditions such as inflammation condition known as PSC and autoimmune hepatitis or AIH. Its pipeline consists of preclinical studies to Phase I trials.
According to website Owler, they have approximately 15 employees. Orbsen Therapeutics was a spin-off from National University of Galway’s Regenerative Medicine Institute (REMEDI . The company has since developed proprietary technologies focused on the isolation of pure and defined stromal cells.